Pliant Therapeutics
PLRX
134 hedge funds and large institutions have $971M invested in Pliant Therapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 16 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
3.52% more ownership
Funds ownership: 104.7% → 108.21% (+3.5%)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding
Funds holding: 134 → 134 (0)
14% less capital invested
Capital invested by funds: $1.14B → $971M (-$165M)
14% less call options, than puts
Call options by funds: $4.2M | Put options by funds: $4.91M
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.26M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$7.67M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6.92M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.8M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$6.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$9.52M |
| 2 |
BlackRock
New York
|
-$2.41M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.23M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.8M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.71M |
PLRX Hedge Fund Activity: Q1 2024 in Review
134 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2024, worth a combined $971M — down 14% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PLRX positions and 16 closed out — a net gain of 1 holder — while 47 added to existing stakes and 36 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $8.26M. The largest seller was Casdin Capital, cutting an estimated $9.52M.
- 134 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $971M of Pliant Therapeutics stock for Q1 2024, down 14% quarter-over-quarter.
- 17 funds opened new Pliant Therapeutics positions in Q1 2024 and 16 closed out, a net change of +1 holder.
- The largest Pliant Therapeutics buyer in Q1 2024 was Deutsche Bank, an estimated $8.26M added.
- The largest Pliant Therapeutics seller in Q1 2024 was Casdin Capital, an estimated $9.52M sold.
Based on aggregated 13F filings for Q1 2024.